MGFR.F Stock Overview
Develops advanced nanomedicine for cancer therapies. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
MagForce AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.001 |
| 52 Week High | €0.001 |
| 52 Week Low | €0.000001 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -99.98% |
| 5 Year Change | n/a |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| MGFR.F | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | 1.7% | 0.3% |
| 1Y | n/a | 21.4% | 31.1% |
Return vs Industry: Insufficient data to determine how MGFR.F performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how MGFR.F performed against the US Market.
Price Volatility
| MGFR.F volatility | |
|---|---|
| MGFR.F Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MGFR.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MGFR.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | n/a | Ben Lipps | www.magforce.de/ |
MagForce AG develops advanced nanomedicine for cancer therapies. It offers NanoTherm therapy system, a combination of medical devices for the treatment of solid brain tumors; NanoPlan, a software that stimulates the temperature distribution in the treatment area; NanoTherm, a magnetic ferrofluid; and NanoActivator, a magnetic field generator. MagForce AG was founded in 1997 and is headquartered in Berlin, Germany.
MagForce AG Fundamentals Summary
| MGFR.F fundamental statistics | |
|---|---|
| Market cap | US$52.54k |
| Earnings (TTM) | -US$11.36m |
| Revenue (TTM) | US$1.16m |
0.0x
P/S Ratio0.0x
P/E RatioIs MGFR.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MGFR.F income statement (TTM) | |
|---|---|
| Revenue | €1.08m |
| Cost of Revenue | €918.75k |
| Gross Profit | €158.39k |
| Other Expenses | €10.73m |
| Earnings | -€10.57m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did MGFR.F perform over the long term?
See historical performance and comparison